--- schema_version: "secwatch.filing_event.v1" accession: "0001654954-23-012952" form_type: "8-K" ticker: null cik: "0001044378" company_name: "BIOCEPT INC" filed_at: "2023-10-16T23:59:59+00:00" generated_at: "2026-06-09T23:03:38.663903+00:00" event_type: "other_material" sentiment: "negative" materiality_score: 1.0 calibrated_materiality_score: 1.0 confidence: "high" source: SEC EDGAR --- # Biocept files Chapter 7 bankruptcy, board and CEO resign ## Summary - Filed voluntary Chapter 7 petition on October 13, 2023 in Delaware Bankruptcy Court. - A Chapter 7 trustee will liquidate assets and pay claims per the Bankruptcy Code. - Entire board (Antonino Morales, Marsha Chandler, Bruce Gerhardt, Quyen Dao-Haddock, Ivor Royston, Linda Rubinstein) resigned effective Oct 13. - CEO Antonino Morales also resigned as President and CEO effective Oct 13. - Resignations not due to disagreements but due to the bankruptcy filing eliminating board powers. ## SEC filing metadata - accession: 0001654954-23-012952 - form_type: 8-K - cik: 0001044378 - company_name: BIOCEPT INC - filed_at: 2023-10-16T23:59:59+00:00 - event_type: other_material - sentiment: negative - materiality_score: 1.0 - calibrated_materiality_score: 1.0 - confidence: high - sec_items: 1.03, 5.02 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1044378/000165495423012952/0001654954-23-012952-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1044378/000165495423012952/biocept_8k.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001654954-23-012952 - JSON: https://secwatch.observer/filing/0001654954-23-012952.json - Plain text: https://secwatch.observer/filing/0001654954-23-012952.txt ## Key facts - Distress & Bankruptcy BIOCEPT INC entered chapter 7 in United States Bankruptcy Court for the District of Delaware (petition 2023-10-13). - Proceeding: chapter 7 - Court: United States Bankruptcy Court for the District of Delaware - Petition: 2023-10-13 source text: Biocept, Inc., a Delaware corporation (the “Company”), filed a voluntary petition for relief (the “Petition”) under the provisions of Chapter 7 of Title 11 of the United States Code, 11 U.S.C. §§ 101 et seq. (the “Code”) in the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”) on October 13, 2023. evidence_url: https://www.sec.gov/Archives/edgar/data/1044378/000165495423012952/0001654954-23-012952-index.htm - Executive change Ivor Royston resigned as Director at BIOCEPT INC. - Action: resigned - Role: Director source text: Antonino Morales, Marsha A. Chandler, Bruce E. Gerhardt, Quyen Dao-Haddock, Ivor Royston, and Linda Rubinstein (each a "Member" and collectively the "Members") tendered their resignations as members of the Company's Board of Directors which resignations were effective on October 13, 2023 evidence_url: https://www.sec.gov/Archives/edgar/data/1044378/000165495423012952/0001654954-23-012952-index.htm - Executive change Antonino Morales resigned as President and Chief Executive Officer at BIOCEPT INC. - Action: resigned - Role: President and Chief Executive Officer source text: In addition to his resignation from the Company's Board of Directors, Mr. Morales tendered his resignation as the Company's President and Chief Executive Officer effective on October 13, 2023 evidence_url: https://www.sec.gov/Archives/edgar/data/1044378/000165495423012952/0001654954-23-012952-index.htm - Executive change Linda Rubinstein resigned as Director at BIOCEPT INC. - Action: resigned - Role: Director source text: Antonino Morales, Marsha A. Chandler, Bruce E. Gerhardt, Quyen Dao-Haddock, Ivor Royston, and Linda Rubinstein (each a "Member" and collectively the "Members") tendered their resignations as members of the Company's Board of Directors which resignations were effective on October 13, 2023 evidence_url: https://www.sec.gov/Archives/edgar/data/1044378/000165495423012952/0001654954-23-012952-index.htm - Executive change Quyen Dao-Haddock resigned as Director at BIOCEPT INC. - Action: resigned - Role: Director source text: Antonino Morales, Marsha A. Chandler, Bruce E. Gerhardt, Quyen Dao-Haddock, Ivor Royston, and Linda Rubinstein (each a "Member" and collectively the "Members") tendered their resignations as members of the Company's Board of Directors which resignations were effective on October 13, 2023 evidence_url: https://www.sec.gov/Archives/edgar/data/1044378/000165495423012952/0001654954-23-012952-index.htm - Executive change Antonino Morales resigned as Director at BIOCEPT INC. - Action: resigned - Role: Director source text: Antonino Morales, Marsha A. Chandler, Bruce E. Gerhardt, Quyen Dao-Haddock, Ivor Royston, and Linda Rubinstein (each a "Member" and collectively the "Members") tendered their resignations as members of the Company's Board of Directors which resignations were effective on October 13, 2023 evidence_url: https://www.sec.gov/Archives/edgar/data/1044378/000165495423012952/0001654954-23-012952-index.htm - Executive change Bruce E. Gerhardt resigned as Director at BIOCEPT INC. - Action: resigned - Role: Director source text: Antonino Morales, Marsha A. Chandler, Bruce E. Gerhardt, Quyen Dao-Haddock, Ivor Royston, and Linda Rubinstein (each a "Member" and collectively the "Members") tendered their resignations as members of the Company's Board of Directors which resignations were effective on October 13, 2023 evidence_url: https://www.sec.gov/Archives/edgar/data/1044378/000165495423012952/0001654954-23-012952-index.htm - Executive change Marsha A. Chandler resigned as Director at BIOCEPT INC. - Action: resigned - Role: Director source text: Antonino Morales, Marsha A. Chandler, Bruce E. Gerhardt, Quyen Dao-Haddock, Ivor Royston, and Linda Rubinstein (each a "Member" and collectively the "Members") tendered their resignations as members of the Company's Board of Directors which resignations were effective on October 13, 2023 evidence_url: https://www.sec.gov/Archives/edgar/data/1044378/000165495423012952/0001654954-23-012952-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.